Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Leishmaniasis

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

American Trypanosomiasis

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.

Trichomoniasis

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.

Toxoplasmosis

Toxoplasmosis

Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Video recording in the delivery room: current status, implications and implementation.

Pediatric research·2021

Same author

[Scientific Day of the Society of Exotic Pathology: Skin and Tropical Diseases November 21, 2019, Val-de-Grâce School, Paris].

Bulletin de la Societe de pathologie exotique (1990)·2020

Same author

[Scientific Day of the Société de pathologie exotique - Rodents in exotic pathology 29 May 2019, Institut Pasteur, Paris].

Bulletin de la Societe de pathologie exotique (1990)·2019

Same author

Negligence.

Medecine et sante tropicales·2019

Same author

Diversity of human African trypanosomiasis epidemiological settings requires fine-tuning control strategies to facilitate disease elimination.

Research and reports in tropical medicine·2018

Same author

[X<sup>e</sup> International Congress of the Société de pathologie exotique, 8-9 November 2017, Haiphong (Vietnam) - Surgery Access in Tropical Areas].

Bulletin de la Societe de pathologie exotique (1990)·2018

Search research articles

Related Experiment Video

Updated: May 29, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Leishmaniasis impact and treatment access.

M den Boer¹, D Argaw, J Jannin

¹Leishmaniasis Control Programme, WHO/IDM. Av. Appia, Geneva, Switzerland.

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases

|September 22, 2011

Summary

Leishmaniasis, a major neglected tropical disease, causes significant global health burdens but lacks adequate attention and accessible treatments. This study highlights issues with leishmaniasis drug access and proposes practical solutions.

More Related Videos

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Published on: December 30, 2012

Related Experiment Videos

Last Updated: May 29, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Published on: December 30, 2012

Area of Science:

Neglected Tropical Diseases
Parasitology
Global Health

Background:

Leishmaniasis is a significant global health issue, ranking third in disease burden among neglected tropical diseases.
It is the second leading cause of parasite-related deaths globally, following malaria.
Despite its impact, leishmaniasis receives insufficient attention and resources, particularly concerning patient treatment access.

Purpose of the Study:

To address the critical problem of poor access to leishmaniasis drugs.
To identify and outline feasible solutions for improving drug accessibility for leishmaniasis patients.

Main Methods:

This study is the first to comprehensively analyze the challenges in accessing leishmaniasis treatments.
It involves identifying key issues contributing to inadequate drug availability and distribution.
Practical and actionable solutions are proposed based on this analysis.

Main Results:

Leishmaniasis drug access is severely limited for affected populations.
Numerous factors contribute to the "unnecessarily and unacceptably poor access" to timely and appropriate treatment.
A range of feasible and practical solutions are presented to overcome these access barriers.

Conclusions:

Improving access to leishmaniasis drugs is crucial for reducing the disease burden.
The proposed solutions offer a roadmap for enhancing treatment availability.
Urgent attention and action are needed to ensure equitable access to leishmaniasis therapies.